Clinical trials: Sexually Transmitted Infection (STI)
HIV Infection
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
The purpose of this study is to evaluate the safety and tolerability of DOR/ISL in adult participants with HIV-1 who had been previously treated with DOR/ISL in earlier clinical studies.
- Trial name
- NCT05766501
- Testing
- DOR/ISL
- Where
- 95 sites in United States, Argentina and 13 more
- Volunteers
- 641 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infection
Discontinuation of Primary and Secondary Prophylaxis for Opportunistic Infections in HIV-infected Patients
The purpose of this study is to compare the incidence of opportunistic infections between HIV-infected patients who continue and discontinue primary or secondary prophylaxis for opportunistic infections in whom receiving…
- Trial name
- NCT01392430
- Testing
- Discontinuation of prophylactic drugs i.e. co-trimoxazole, dapsone, fluconazole, itraconazole, azithromycin
- Where
- Thailand
- Volunteers
- 74 people
- Sponsor
- Chiang Mai University
HIV (Human Immunodeficiency Virus), Chlamydia
Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland
The main goal of the observational study is to evaluate participants' satisfaction with free HIV and sexually transmitted infection (STI) testing and counselling offered by the cities of Lucerne and Zurich, Switzerland to young…
- Conditions
- HIV (Human Immunodeficiency Virus), Chlamydia, Gonorrhea, Syphilis
- Trial name
- feSTI (NCT07516912)
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- University of Zurich
HIV Infections
Study to Evaluate the Influence of Nevirapine to Atazanavir in Steady State Equilibrium in HIV Patients
The purpose of this study is to evaluate the influence of nevirapine in exposure to atazanavir boosted with ritonavir, in steady state equilibrium, in HIV-infected adult patients.
- Trial name
- NCT00355719
- Testing
- Atazanavir (Reyataz), Ritonavir (Norvir), Nevirapine (Viramune)
- Where
- 2 sites in Spain
- Volunteers
- 14 people
- Sponsor
- Germans Trias i Pujol Hospital
HIV Infections
Pilot Study to Evaluate the Efficacy of Zidovudine in Preventing CD4+ Lymphocyte Decline in Patients With Primary HIV Infection. (One Treatment Arm Receives Placebo)
To evaluate the safety and efficacy of early treatment with zidovudine for preventing a decline in CD4+ lymphocyte counts in patients with primary HIV infection.
- Trial name
- NCT00000765
- Testing
- Zidovudine
- Where
- 9 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Telerehabilitation, Neuropsychology
Teleneuropsychological Intervention in Asymptomatic HIV Seropositive Patients: N&C NeuroChange
Currently 37.9 million people are living with human immunodeficiency virus (HIV) around the world (UNAIDS, 2018). Even with antiretroviral treatment (ART), the virus enters the central nervous system and can affect the following…
- Conditions
- Telerehabilitation, Neuropsychology, HIV Dementia
- Trial name
- NCT05571761
- Testing
- Cognitive stimulation program
- Where
- Mexico
- Sponsor
- Universidad Nacional Autonoma de Mexico
HIV Infections
A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome
The purpose of this clinical research study is to learn if BMS-232632 administered as Atazanavir/ritonavir (ATV/RTV) is superior to an anti-retroviral regimen including Lopinavir/ritonavir (LPV/RTV), as assessed by an increased…
- Trial name
- NCT00312754
- Testing
- Atazanavir
- Where
- 6 sites in France
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
HIV, Mental Health
Stepped Care for Youth Living With HIV
Optimizing the HIV Treatment Continuum with a Stepped Care Model for Youth Living with HIV (YLH) aims to achieve viral suppression among YLH.
- Conditions
- HIV, Mental Health, Illicit Substance Use, Sexually Transmitted Infections (STI)
- Trial name
- NCT03109431
- Testing
- Level 1, Level 2, Level 3
- Where
- 2 sites in United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Tuberculosis, HIV Infections
Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)
HIV-infected people have an increased risk of developing active tuberculosis (TB). At the time the study was designed, the standard course of treatment for TB was 6 to 9 months of isoniazid (INH).This study compared the safety…
- Trial name
- NCT01404312
- Testing
- Rifapentine (RPT), Isoniazid (INH), Pyridoxine (Vitamin B6)
- Where
- 45 sites in United States, Botswana and 8 more
- Volunteers
- 3,000 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Love Infection: A Dramatized Story Intervention (Telenovela/Soap Opera) for HIV Prevention
Purpose: To test the feasibility, acceptability of the IA intervention (four telenovela episodes), assessment of the mechanisms of action (self-efficacy, narrative engagement, and emotional elicitation) and conduct a randomized…
- Trial name
- IA (NCT05358366)
- Testing
- Infeccion de Amor (Love Infection)
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Treponema Pallidum Infection, Chlamydia Trachomatis Infection
Improving Maternal and Child Health Through Point-of-care STI Testing
The goal of this clinical trial is to learn if point-of-care tests (POCTs) for sexually transmitted infections (STIs) improve the timely treatment of syphilis, chlamydia, gonorrhea, and trichomonas in pregnant women.
- Conditions
- Treponema Pallidum Infection, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Trichomonas Vaginalis Vaginitis
- Trial name
- MATCH-POINT (NCT07290439)
- Testing
- Point-of-care STI tests, Standard of care STI testing
- Where
- United States
- Volunteers
- 756 people, healthy volunteers welcome
- Sponsor
- Emory University
Peripheral Neuropathy, HIV Infections
Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy
To evaluate the safety and efficacy of pregabalin in reducing neuropathic pain associated with HIV neuropathy
- Trial name
- NCT00264875
- Testing
- pregabalin
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 220 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
HIV Infections, AIDS
Test Albuvirtide in Experienced Patients
The purpose of this study is to evaluate the efficacy and safety of albuvirtide combined with lopinavir-ritonavir (LPV/r) in HIV-1-infected patients who failed first-line antiretroviral therapy (ART).
- Trial name
- TALENT (NCT02369965)
- Testing
- albuvirtide, lopinavir-ritonavir, tenofovir
- Where
- 12 sites in China
- Volunteers
- 418 people
- Sponsor
- Frontier Biotechnologies Inc.
HIV/AIDS
INcentives and ReMINDers to Improve Long-term Medication Adherence
The study will test the feasibility and acceptability of using text messages and behavioral economics-based incentives to support anchoring Anti-Retroviral Therapy (ART) adherence to an existing routine in order to improve…
- Trial name
- INMIND (NCT05131165)
- Testing
- Daily Text Messages, Incentivization based on timely ART adherence
- Where
- Uganda
- Volunteers
- 166 people
- Sponsor
- RAND
HIV Infections
A Comparison of Zidovudine (AZT) and Stavudine in HIV-Infected Patients
To compare stavudine (d4T) and zidovudine (AZT) in slowing the progression of HIV disease. To compare the antiviral activity of d4T versus AZT as measured by plasma levels of p24 antigen and HIV viremia, and their relative…
- Trial name
- NCT00002307
- Testing
- Stavudine, Zidovudine
- Where
- 45 sites in United States, Puerto Rico
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Safety and Pharmacokinetics of Intravaginal Rings Containing Vicriviroc (MK-4176) and/or MK-2048
Research is currently underway to develop new HIV prevention strategies. Intravaginal rings (IVRs) are one drug delivery method that is currently being studied.
- Trial name
- NCT02356302
- Testing
- Vicriviroc (MK-4176) Intravaginal Ring (IVR), MK-2048 IVR, MK-2048A IVR
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Trial of Two Doses of 2',3'-Dideoxycytidine (ddC) in the Treatment of Children With Symptomatic HIV Infection Who Are Intolerant of AZT and/or Who Show Progressive Disease While on AZT
To evaluate and compare the long-term (48-177 weeks) safety, tolerance, and efficacy of two doses of zalcitabine ( dideoxycytidine; ddC ) taken orally every 8 hours in children with symptomatic HIV infection who have one of the…
- Trial name
- NCT00000653
- Testing
- Zalcitabine
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 140 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Peri-Implantitis
Peri-implantitis in HIV-positive Patients With Different Dental Prosthesis
Dental implants are widely used in human immunodeficiency virus (HIV)-positive patients, but the interaction between immune status and success of implant therapy, especially in such patients, is not clear.
- Trial name
- PERIHIV (NCT04983212)
- Testing
- periodontal control
- Where
- Italy
- Volunteers
- 85 people
- Sponsor
- Università Vita-Salute San Raffaele
Syphilis
Syphilis Response to Higher Penicillin Dosage: The 2.4 Versus 7.2 Study
Syphilis remains a significant health problem worldwide, with an estimated 10.6 million new cases per year. Due to shared transmission route and risk factors, co-infection with syphilis and Human Immunodeficiency Virus (HIV) is…
- Trial name
- NCT02611765
- Testing
- Benzathine penicillin G intramuscular 7.2 million units, Benzathine penicillin G intramuscular 2.4 million units
- Volunteers
- 64 people
- Sponsor
- Baylor College of Medicine
HIV Infections
Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients
The general aim is to evaluate the antiviral activity and safety of increasing doses of oral administered RTV-boosted BILR 355 BS (75 mg and 150 mg twice daily) in HIV-1-infected, NNRTI-experienced patients, followed by 28 day…
- Trial name
- NCT00294372
- Testing
- BILR 355 BS
- Where
- 11 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.